These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 4-Anilino-7,8-dialkoxybenzo[g]quinoline-3-carbonitriles as potent Src kinase inhibitors. Berger DM; Dutia M; Birnberg G; Powell D; Boschelli DH; Wang YD; Ravi M; Yaczko D; Golas J; Lucas J; Boschelli F J Med Chem; 2005 Sep; 48(19):5909-20. PubMed ID: 16161995 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525 [TBL] [Abstract][Full Text] [Related]
6. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Shakespeare W; Yang M; Bohacek R; Cerasoli F; Stebbins K; Sundaramoorthi R; Azimioara M; Vu C; Pradeepan S; Metcalf C; Haraldson C; Merry T; Dalgarno D; Narula S; Hatada M; Lu X; van Schravendijk MR; Adams S; Violette S; Smith J; Guan W; Bartlett C; Herson J; Iuliucci J; Weigele M; Sawyer T Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9373-8. PubMed ID: 10944210 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-tyrosine kinase activity of 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives: investigation of their role against p60c-Src receptor tyrosine kinase with the application of receptor docking studies. Olgen S; Akaho E; Nebioglu D Farmaco; 2005; 60(6-7):497-506. PubMed ID: 15927182 [TBL] [Abstract][Full Text] [Related]
8. Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Wang Y; Metcalf CA; Shakespeare WC; Sundaramoorthi R; Keenan TP; Bohacek RS; van Schravendijk MR; Violette SM; Narula SS; Dalgarno DC; Haraldson C; Keats J; Liou S; Mani U; Pradeepan S; Ram M; Adams S; Weigele M; Sawyer TK Bioorg Med Chem Lett; 2003 Sep; 13(18):3067-70. PubMed ID: 12941335 [TBL] [Abstract][Full Text] [Related]
9. SRC inhibitors in metastatic bone disease. Boyce BF; Xing L; Yao Z; Yamashita T; Shakespeare WC; Wang Y; Metcalf CA; Sundaramoorthi R; Dalgarno DC; Iuliucci JD; Sawyer TK Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6291s-6295s. PubMed ID: 17062716 [TBL] [Abstract][Full Text] [Related]
10. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues. Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334 [TBL] [Abstract][Full Text] [Related]
11. Novel aminomethylindole derivatives as inhibitors of pp60c-Src tyrosine kinase: synthesis and biological activity. Işgör YG; Kiliç Z; Olgen S Chem Biol Drug Des; 2008 Dec; 72(6):599-604. PubMed ID: 19090928 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Wang WY; Hsieh PW; Wu YC; Wu CC Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity. Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors. Pevet I; Brulé C; Tizot A; Gohier A; Cruzalegui F; Boutin JA; Goldstein S Bioorg Med Chem; 2011 Apr; 19(8):2517-28. PubMed ID: 21459579 [TBL] [Abstract][Full Text] [Related]
16. Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors. Wang Y; Shakespeare WC; Huang WS; Sundaramoorthi R; Lentini S; Das S; Liu S; Banda G; Wen D; Zhu X; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Dalgarno D; Clackson T; Sawyer TK Bioorg Med Chem Lett; 2008 Sep; 18(17):4907-12. PubMed ID: 18691885 [TBL] [Abstract][Full Text] [Related]
17. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. Yoneda T; Lowe C; Lee CH; Gutierrez G; Niewolna M; Williams PJ; Izbicka E; Uehara Y; Mundy GR J Clin Invest; 1993 Jun; 91(6):2791-5. PubMed ID: 8514886 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors. Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiviral activity of N9-[3-fluoro-2-(phosphonomethoxy)propyl] analogues derived from N6-substituted adenines and 2,6-diaminopurines. Baszczyňski O; Jansa P; Dračínský M; Klepetářová B; Holý A; Votruba I; de Clercq E; Balzarini J; Janeba Z Bioorg Med Chem; 2011 Apr; 19(7):2114-24. PubMed ID: 21429755 [TBL] [Abstract][Full Text] [Related]
20. Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Vu CB; Luke GP; Kawahata N; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keenan TP; Pradeepan S; Corpuz E; Merry T; Bohacek RS; Dalgarno DC; Narula SS; van Schravendijk MR; Ram MK; Adams S; Liou S; Keats JA; Violette SM; Guan W; Weigele M; Sawyer TK Bioorg Med Chem Lett; 2003 Sep; 13(18):3071-4. PubMed ID: 12941336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]